BURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS treatment in Israel. BrainsWay has steadily increased its presence in the country with 11 recent system installations, and this momentum has been driven in part by a 45% increase in reimbursement rates. The Company expects to have additional Deep TMS systems installed in Israel by the end of 2024. <\/p>\n
BrainsWay continues to make significant strides in expanding its international footprint, and it is extremely meaningful for us to be able to offer our life altering Deep TMS therapy to mental health patients across Israel, said Hadar Levy, Chief Executive Officer of BrainsWay. Following recent events in the country, serious mental health conditions are on the rise, and it is profoundly important to us that Deep TMS be made available to as many patients as possible, concluded Mr. Levy. <\/p>\n
\"This innovative technology represents a significant opportunity to treat numerous patients, including many who have not responded to medication, said Reut Filipowicz, BrainsWays Head of Business Development for the Israeli market. We are excited to bring Deep TMS to those suffering from mental health conditions who are truly in need of additional treatment solutions.\" <\/p>\n
About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visitwww.brainsway.com. <\/p>\n
Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and\/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Companys anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and\/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Companys intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. <\/p>\n
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission. <\/p>\n
Contacts: BrainsWay: Ido Marom Chief Financial Officer Ido.Marom@BrainsWay.com<\/a> <\/p>\n Investors: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com<\/a> <\/p>\n Media Contact: Chris Boyer Vice President, Marketing Chris.Boyer@BrainsWay.com<\/a> <\/p>\n<\/p>\n <\/p>\n Read the original here: <\/p>\n BrainsWay Expands Deep TMS Access in Israel Following Significant Increase in Reimbursement Rates - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" BURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS treatment in Israel Continue reading